Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class. A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and voglibose among newly diagnosed Type 2 diabete
Cat.No
DC5076
Name
Alogliptin Benzoate
Chemical Properties
CAS
850649-62-6
Formula
C18H21N5O2.C7H6O2
MW
461.513
Storage
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
References
[1]. Rendell M, et al. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 Mar;13(4):553-63.
[2]. Radha Andukuri, et al. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009; 2: 117-126.
[3]. Takeuchi K, et al. Pharmacological and clinical profile of alogliptin benzoate (NESINA?).Nihon Yakurigaku Zasshi. 2011 Jan;137(1):43-50.
[4]. Moritoh Y, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
